Background Roche Diagnostics has issued new c-fas calibrators for its automated systems. These produce creatinine values that are more comparable with those obtained by high-performance liquid chromatography. However, this results in an underestimation of measured creatinine at concentrations below 155 mmol/L and an overestimation at concentrations above this value.
Methods Serum and urine creatinine concentrations were prospectively determined on samples from 60 patients using the new (compensated) and old (uncompensated) c-fas calibrators, and Passing-Bablok regression analysis was performed. The regression equations thus determined were then used retrospectively to determine the compensated creatinine results (i.e. those results that would have been obtained using the new calibrator) in those serum and urine samples analysed in the previous year using the old uncompensated c-fas calibrator. The compensated creatinine results were then used to estimate the glomerular filtration rate (GFR) by calculating creatinine clearance. This was done by using the formula: UV/Pt, in which U represents the urinary creatinine concentration (mmol/L), V the urinary collection volume (mL), P the serum creatinine concentration (mmol/L) and t the urinary collection time (min). It was also calculated using the abbreviated Modification of Diet in Renal Disease study group (MDRD) formula.
Introduction
Glomerular ¢ltration rate (GFR) is important to clinicians for assessing renal function. The best estimation of GFR is to determine the clearance of a compound inert to renal tubules, such as inulin. However, this procedure is too inconvenient and expensive for everyday use. In routine practice, GFR is estimated by determining creatinine clearance. In the majority of laboratories, creatinine is measured using the Ja¡e¤ alkaline^picrate method, which is inexpensive and readily automated.
The earliest Ja¡e¤ method included a de-proteinization step to remove pseudo-chromogens contributed by proteins. 1 However, present-day multi-channel analysers use undiluted serum or plasma, making them susceptible to the so-called 'protein error', 2 which produces a positive bias of *27 mmol/L when compared with the high-performance liquid chromatography (HPLC) reference method. 3 In order to improve correlation between the Ja¡e¤ method and HPLC, Roche Diagnostics has issued new c-fas calibrators that produce compensated creatinine results that are more comparable with those obtained by HPLC. 4 The compensated values produced by these calibrators will result in an underestimation of serum creatinine in those samples with a concentration below the 155 mmol/L set-point value of the calibrator and an overestimate in samples with a concentration above this value. 5 Although this adjustment produces a better correlation between compensated and reference methods, the slopes of the correlation equations of creatinine clearance determined by the compensated and uncompensated methods using the Cockcroft^Gault algorithm, the calculation of the Modi¢cation of Diet in Renal Disease study group (MDRD) or the Schwartz algorithm can vary from 0.46 to 0.80. 5 This may result in clinicians having to adjust their action limits for patient management, especially in patients undergoing dialysis.
Patients and methods
We conducted this retrospective study in a 1400-bed teaching hospital with renal dialysis and transplantation units. Serum and urine creatinine results from the DP Modular Analyser (Roche Diagnostics Corp, Indianapolis, IN, USA) were retrieved for 1 year (1 July 2002 to 30 June 2003) and used for calculating 24-h urine creatinine clearance. Passing^Bablok regression equations for serum and urine creatinine were ¢rst determined from a prospective collection of samples from 60 patients with a wide range of renal function (serum creatinine concentration 321 408 mmol/L). Samples were analysed using the compensated (y) and uncompensated (x) methods and the regression equations determined. For serum, the regression equation was: y ¼1.17x726.03, correlation coe⁄cient (r) ¼ 1.00, P50.0001, equation 1; for urine, it was: y ¼1.16x+4.49, r ¼ 0.999, P50.0001, equation 2. These equations were then used to calculate compensated creatinine values on the data that had been retrieved retrospectively. The compensated serum and urine creatinine values were then used to calculate creatinine clearance by two methods. Firstly, by using the formula: UV/Pt, in which U represents the urinary creatinine concentration (mmol/L),V the urinary collection volume (mL), P the serum creatinine concentration (mmol/L) and t the urinary collection time (min). Secondly, by using the abbreviated MDRD formula: GFR ¼1866[serum creatinine (mmol/L)/88.4] 71.154 6(age) 70.203 6(0.742 if female)6(1.210 if African^American). 6 The compensated and uncompensated creatinine clearance values obtained by each of the two calculations were then analysed using the Passing^Bablok regression analysis. In addition, Bland^Altman plots were determined. Additional sub-group analysis was performed in samples with serum creatinine concentrations above and below 155 mmol/L set-point calibrator and also in samples with concentrations above and below 500 mmol/L, the clinical threshold for introduction of dialysis.
Results and discussion
In total, there were 6133 complete sets of historical creatinine clearance and serum and urine creatinine results retrieved. They comprised 3070 from women aged 17^92 years (median ¼ 46 years) and 3063 from men aged 2^92 years (median ¼ 54 years). PassingB ablok regression parameters and description of the Bland^Altman plots are summarized in Table 1 . Although there was a high correlation between creatinine clearance (calculated using the formula: UV/Pt) obtained using the two calibrators, the values obtained using the new compensated calibrator were generally overestimated by *27% at serum concentrations below 155 mmol/L. However, in patients with a serum creatinine concentration above 155 mmol/L, the slope and intercept of the regression equation became 1.02 and 70.40, respectively, indicating that this overestimation had largely disappeared. Similar ¢ndings were obtained in those patients with a serum creatinine concentration above 500 mmol/L, for whom the slope and intercept were 0.93 and 70.02, respectively. These results suggest that any change in measured creatinine clearance would be minimal in patients su¡ering from mild to moderate renal failure (serum creatinine between 155 and 500 mmol/L). This is because changes in the numerator and denominator of the equation used to calculate the clearance (UV/Pt) e¡ectively cancel each other out. 6 Interestingly, this phenomenon also occurred in calculating the compensated creatinine clearance using the MDRD formula. For patients with a serum creatinine concentration above 155 mmol/L, the slope and intercept of the regression equation were 0.99 and 70.85, respectively, suggesting that overestimation of creatinine clearance as calculated using the MDRD formula had largely disappeared. For patients with a serum creatinine concentration above 500 mmol/L, the slope and intercept of the regression equation were 0.89 and 70.14, respectively. Therefore, as long as the serum creatinine concentration was above155 mmol/L, the e¡ect of adjusting an absolute value of 26 mmol/L (y-intercept from equation 1) followed by reciprocal manipulation in the abbreviated MDRD formula would only lead to minimal changes in the ¢nal numerical result. However, when serum creatinine concentration decreased to below 155 mmol/L, the same mathematical adjustment would lead to a gross overestimation of GFR.
Conclusion
It is concluded that for patients with renal impairment (serum creatinine concentration 4155 mmol/L), change of creatinine method from uncompensated to compensated Ja¡e¤ reaction should have minimal e¡ect on the estimation of GFR, either by calculation of creatinine clearance using the formula: UV/Pt or by using the MDRD formula. However, the change of method can result in gross overestimation of GFR in patients with normal renal function. It may therefore be appropriate for laboratories to discuss the impact of the introduction of this new calibrator with those clinical sta¡ who monitor patients using creatinine clearance values.
